{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"65.2","value":"30.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Will report the percentage of patients within each disease stratum who experienced a grade 3 or higher toxicity with attribution of possible, probable, or definite while on protocol therapy or within 30 days of the last dose of therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.","id":"OG000","title":"Treatment (Trametinib)"}],"paramType":"NUMBER","populationDescription":"All patients who met the evaluable for response criteria outlined in section 9.4 of the ADVL1521 protocol.","reportingStatus":"POSTED","timeFrame":"Up to cycle 12 (1 cycle = 28 days)","title":"Incidence of Adverse Events","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}